Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Event Coronary Artery Bypass Graft Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Herzchirurgie University Hospital Basel

Basel, 4031, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012

Exclusion criteria

disapproval of use of data for research purposes

Treatment and study plan

Coronary Bypass Revascularization

Procedure

analysis of perioperative major cardiovascular events in diabetic patients

Primary outcomes

occurence of Major adverse cardiac events

Time frame: perioperative = in hospital

myocardial infarction, cardiac related death, stroke

Secondary outcomes

occurence of severe renal insufficiency

Time frame: perioperative = in hospital

application of renal replacement therapy (renal dialysis)
occurence of sternal wound infection

Time frame: perioperative = in hospital

sternal wound infection
mortality

Time frame: perioperative = in hospital

death rate perioperative

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Official study title

Glycosylated Hemoglobin and the Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization

Important dates

Study start: 2017
Primary completion: 2018
Study completion: 2018
First posted: Jul 18, 2018
Registry last updated: Apr 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed